CA2227891A1 - Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations - Google Patents

Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations

Info

Publication number
CA2227891A1
CA2227891A1 CA002227891A CA2227891A CA2227891A1 CA 2227891 A1 CA2227891 A1 CA 2227891A1 CA 002227891 A CA002227891 A CA 002227891A CA 2227891 A CA2227891 A CA 2227891A CA 2227891 A1 CA2227891 A1 CA 2227891A1
Authority
CA
Canada
Prior art keywords
therapeutic agent
insulin
polymer
coupled
another
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002227891A
Other languages
French (fr)
Other versions
CA2227891C (en
Inventor
Nnochiri Nkem Ekwuribe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocon Ltd
Original Assignee
Protein Delivery, Inc.
Nnochiri Nkem Ekwuribe
Nobex Corporation
Biocon Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Delivery, Inc., Nnochiri Nkem Ekwuribe, Nobex Corporation, Biocon Limited filed Critical Protein Delivery, Inc.
Publication of CA2227891A1 publication Critical patent/CA2227891A1/en
Application granted granted Critical
Publication of CA2227891C publication Critical patent/CA2227891C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Abstract

A stabilized conjugated therapeutic agent complex comprising a therapeutic agent conjugatively coupled to a polymer including lipophilic and hydrophilic moieties. In a particular aspect, the invention comprises an insulin composition suitable for parenteral as well as non-parenteral administration, preferably oral or parenteral administration, comprising insulin covalently coupled with a polymer including:
(i) a linear polyalkylene glycol moiety and (ii) a lipophilic moiety, wherein the insulin, the linear polyalkylene glycol moiety and the lipophilic moiety are conformationally arranged in relation to one another such that the insulin in the composition has enhanced in vivo resistance to enzymatic degradation, relative to insulin alone. One, two, or three polymer constituents may be covalently attached to the therapeutic agent molecule, with one polymer constituent being preferred.
The conjugates of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications, and the therapeutic agent and polymer may be covalently coupled to one another, or alternatively may be associatively coupled to one another, e.g., by hydrogen bonding or other associative bonding relationship.
CA002227891A 1995-07-31 1996-07-29 Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations Expired - Lifetime CA2227891C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/509,422 US5681811A (en) 1993-05-10 1995-07-31 Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US509,422 1995-07-31
PCT/US1996/012425 WO1997004796A1 (en) 1995-07-31 1996-07-29 Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations

Publications (2)

Publication Number Publication Date
CA2227891A1 true CA2227891A1 (en) 1997-02-13
CA2227891C CA2227891C (en) 2009-04-14

Family

ID=24026590

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002227891A Expired - Lifetime CA2227891C (en) 1995-07-31 1996-07-29 Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations

Country Status (8)

Country Link
US (1) US5681811A (en)
EP (1) EP0841936A4 (en)
JP (1) JPH11511131A (en)
CN (1) CN1182870C (en)
AU (1) AU698944B2 (en)
CA (1) CA2227891C (en)
IL (1) IL123106A0 (en)
WO (1) WO1997004796A1 (en)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
KR100361933B1 (en) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 Chemically defined nonpolymeric bonds form the platform molecule and its conjugate
US20030119724A1 (en) * 1995-11-22 2003-06-26 Ts`O Paul O.P. Ligands to enhance cellular uptake of biomolecules
US6503881B2 (en) 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6180604B1 (en) 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
PL333364A1 (en) 1996-11-14 1999-12-06 Biota Scient Management Novel compounds and method of using them
US6492501B1 (en) 1996-12-16 2002-12-10 Jean-Luc Popot Water soluble acrylic membrane-polymer protein amphiphilic complex and application to diagnosis methods
US7135191B2 (en) * 1997-09-04 2006-11-14 Zsolt Istvan Hertelendy Urogenital or anorectal transmucosal vaccine delivery system
US6107489A (en) * 1998-03-17 2000-08-22 Conjuchem, Inc. Extended lifetimes in vivo renin inhibitors
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
PT1121382E (en) * 1998-10-16 2006-10-31 Biogen Idec Inc BETA INTERFERENCE FUSE PROTEINS AND THEIR RESPECTIVE USES
US6277830B1 (en) * 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
PT1121156E (en) 1998-10-16 2006-05-31 Biogen Idec Inc CONJUGATES OF INTERFERRO-BETA-1A POLYMERS AND THEIR USES
US6458953B1 (en) * 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
CA2376057A1 (en) * 1999-06-08 2000-12-14 La Jolla Pharmaceutical Company Valency platform molecules comprising aminooxy groups
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
CZ299516B6 (en) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Erythropoietin glycoprotein conjugate, process for its preparation and use and pharmaceutical composition containing thereof
KR100345214B1 (en) * 1999-08-17 2002-07-25 이강춘 The nasal transmucosal delivery of peptides conjugated with biocompatible polymers
US6713454B1 (en) * 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
MXPA02003176A (en) * 1999-10-04 2002-09-30 Shearwater Corp Polymer stabilized neuropeptides.
US6638906B1 (en) * 1999-12-13 2003-10-28 Nobex Corporation Amphiphilic polymers and polypeptide conjugates comprising same
KR20090007504A (en) 2000-02-24 2009-01-16 몬산토 테크놀로지 엘엘씨 Non-aqueous injectable formulations for extended release of somatotropin
US6924270B2 (en) 2000-04-20 2005-08-02 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US6951939B2 (en) 2000-06-08 2005-10-04 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
AU2001271491A1 (en) 2000-06-26 2002-01-08 Monsanto Technology Llc Non-aqueous surfactant-containing formulations for extended release of somatotropin
US6664234B1 (en) 2000-06-30 2003-12-16 Monsanto Technology Llc Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
EP1318827A4 (en) * 2000-09-08 2005-09-14 Gryphon Therapeutics Inc Polymer-modified synthetic proteins
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
JP2004536027A (en) 2000-12-01 2004-12-02 ジョーンズ・ホプキンス・ユニーバーシティー Glycosylated / galactosylated peptide conjugates, bifunctional linkers, and nucleotide monomers / polymers, and related compositions and methods of use
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
WO2002089830A1 (en) * 2001-05-04 2002-11-14 North Carolina State University Polymer conjugates of insecticidal peptides or nucleic acids and methods of use thereof
US20030108585A1 (en) * 2001-05-04 2003-06-12 Roe R. Michael Polymer conjugates of insecticidal peptides or nucleic acids or insecticides and methods of use thereof
IL158862A0 (en) * 2001-05-21 2004-05-12 Nektar Therapeutics An insulin composition for pulmonary administration
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US7713932B2 (en) * 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US20040101941A1 (en) * 2001-07-26 2004-05-27 Sara Lavi Intracellular delivery system for protein phosphatases
US7008650B2 (en) * 2001-08-09 2006-03-07 Lam Paul Y S Compositions for the treatment of acquired immunodeficiency disease
US6835536B2 (en) 2001-08-21 2004-12-28 Micrologix Biotech Inc. Antimicrobial cationic peptides and formulations thereof
US20060014697A1 (en) 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
CA2457885A1 (en) 2001-08-24 2003-03-06 Micrologix Biotech Inc. Antimicrobial and anti-inflammatory peptides
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
DK1430082T3 (en) 2001-09-07 2010-01-18 Biocon Ltd Process for the Synthesis of Insulin Polypeptide Oligomer Conjugates and Proinsulin Polypeptide Oligomer Conjugates and Method for Synthesis thereof
MXPA04004336A (en) * 2001-11-07 2005-05-16 Nektar Therapeutics Al Corp Branched polymers and their conjugates.
US7262164B2 (en) * 2001-11-09 2007-08-28 Enzon, Inc. Polymeric thiol-linked prodrugs employing benzyl elimination systems
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
RS55578B1 (en) * 2002-01-18 2017-06-30 Biogen Ma Inc Polyalkylene polymer compounds and uses thereof
US20030167556A1 (en) * 2002-03-05 2003-09-11 Consumers Choice Systems, Inc. Methods and devices for transdermal delivery of anti-aging compounds for treatment and prevention of facial or neck skin aging
US7459435B2 (en) * 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US20040152769A1 (en) * 2002-11-09 2004-08-05 Ekwuribe Nnochiri Nkem Modified carbamate-containing prodrugs and methods of synthesizing same
US20040171860A1 (en) * 2002-11-12 2004-09-02 Hong Zhao Novel acylating reagents
AU2003295432A1 (en) 2002-11-12 2004-06-03 Enzon Pharmaceuticals, Inc. Prodrugs of vancomycin with hydrolysis resistant polymer linkers
US7273845B2 (en) * 2002-11-12 2007-09-25 Enzon Pharmaceuticals, Inc. Polymeric prodrugs of vancomycin
US7008177B2 (en) * 2002-11-14 2006-03-07 Cummins Inc. Centrifugal pump with self cooling and flushing features
US7459436B2 (en) * 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
CA2504287A1 (en) 2002-11-26 2004-06-10 Nobex Corporation Natriuretic compounds, conjugates, and uses thereof
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
US8133881B2 (en) 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7812120B2 (en) * 2003-03-21 2010-10-12 Par Pharmaceutical, Inc. Nasal calcitonin formulations containing chlorobutanol
PL1651249T3 (en) 2003-07-23 2013-04-30 Novartis Ag Use of calcitonin in osteoarthritis
PT1660047E (en) 2003-08-13 2014-02-27 Biocon Ltd Micro-particle fatty acid salt solid dosage formulations for therapeutic agents
WO2005058347A1 (en) * 2003-12-19 2005-06-30 F. Hoffmann-La Roche Ag Use of erythropoietin in the treatment of disturbances of iron distribution in chronic inflammatory intestinal diseases
US20050143303A1 (en) * 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US20060074025A1 (en) * 2003-12-26 2006-04-06 Nastech Pharmaceutical Company Inc. Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
US20080318837A1 (en) * 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US20060210614A1 (en) * 2003-12-26 2006-09-21 Nastech Pharmaceutical Company Inc. Method of treatment of a metabolic disease using intranasal administration of exendin peptide
WO2005094897A2 (en) * 2004-04-01 2005-10-13 Cardiome Pharma Corp. Pegylated ion channel modulating compounds
ES2618028T3 (en) 2004-07-19 2017-06-20 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof.
EP1773376A4 (en) 2004-08-03 2009-07-01 Emisphere Tech Inc Antidiabetic oral insulin-biguanide combination
WO2006076471A2 (en) * 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
EP1926768B1 (en) 2005-07-18 2011-09-14 Nektar Therapeutics Branched functionalized polymers using branched polyol cores
US20080234206A1 (en) * 2005-09-13 2008-09-25 Shire Llc Prodrugs of Phentermine
JP2009515993A (en) 2005-11-17 2009-04-16 ノバルティス アクチエンゲゼルシャフト Pharmaceutical composition
WO2007067964A2 (en) * 2005-12-08 2007-06-14 Nastech Pharmaceutical Company Inc. Mucosal delivery of stabilized formulations of exendin
KR101872061B1 (en) 2005-12-19 2018-06-27 파마인 코포레이션 Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
GB0604187D0 (en) * 2006-03-02 2006-04-12 Fusion Antibodies Ltd Peptide and uses thereof
BRPI0709427A2 (en) * 2006-03-30 2011-07-12 Palatin Technologies Inc "Cyclic construct, pharmaceutical composition and use of a compound
CA2647146A1 (en) * 2006-03-30 2007-10-11 Palatin Technologies, Inc. Linear natriuretic peptide constructs
US8580746B2 (en) * 2006-03-30 2013-11-12 Palatin Technologies, Inc. Amide linkage cyclic natriuretic peptide constructs
EA200870575A1 (en) 2006-05-26 2009-08-28 Амилин Фармасьютикалз, Инк. COMPOSITIONS AND METHODS OF TREATMENT OF CONSTITUAL HEART FAILURE
GB0611405D0 (en) * 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
US8501693B2 (en) * 2006-08-04 2013-08-06 Amylin Pharmaceuticals, Llc Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen
WO2008033910A2 (en) * 2006-09-12 2008-03-20 Tunac Josefino B Punctum: drug delivery site for therapeutic peptides and proteins
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
WO2009017662A2 (en) * 2007-07-27 2009-02-05 Immuneregen Biosciences, Inc. Method of using substance p analogs for treatment amelioration of myelodysplastic syndrome
US8741858B2 (en) * 2007-09-21 2014-06-03 Zhongxu Ren Oligomer-nucleoside phosphate conjugates
AU2008313248B2 (en) 2007-10-16 2012-04-26 Biocon Limited An orally administerable solid pharmaceutical composition and a process thereof
US20090176892A1 (en) 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
US8466276B2 (en) 2008-02-22 2013-06-18 Nektar Therapeutics Oligomer conjugates of heteropentacyclic nucleosides
KR20200000462A (en) 2008-08-15 2020-01-02 아이언우드 파마슈티컬스, 인코포레이티드 Linaclotide-containing formulations for oral administration
WO2011003633A1 (en) 2009-07-06 2011-01-13 Alize Pharma Ii Pegylated l-asparaginase
WO2011012718A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Prodrugs comprising an insulin linker conjugate
ES2636741T3 (en) 2009-07-31 2017-10-09 Sanofi-Aventis Deutschland Gmbh Long-acting insulin composition
JP2013501071A (en) 2009-08-06 2013-01-10 アイロンウッド ファーマシューティカルズ， インコーポレイテッド Formulations containing linaclotide
CA2784793A1 (en) 2009-12-21 2011-07-21 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
CA2784800A1 (en) 2009-12-21 2011-07-21 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
US20110236878A1 (en) * 2010-01-25 2011-09-29 Ivan Correia Rapid Characterization of Proteins in Complex Biological Fluids
TR201711271T4 (en) 2010-02-17 2019-02-21 Ironwood Pharmaceuticals Inc Treatments for Gastrointestinal Disorders
PL2603232T3 (en) 2010-08-11 2020-05-18 Ironwood Pharmaceuticals, Inc. Stable formulations of linaclotide
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
US20130344053A1 (en) 2010-12-28 2013-12-26 University Of Rochester Methods of Modifying Insulin Signaling Using Biliverdin Reductase (BVR) and BVR Derived Peptides
WO2012122059A1 (en) 2011-03-04 2012-09-13 New York University Hydrogen bond surrogate macrocycles as modulators of ras
EP2776055B1 (en) 2011-08-17 2016-12-14 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
LT2753346T (en) 2011-09-07 2020-08-10 Mount Sinai School Of Medicine Ceramidase and cell differentiation
JP2015508779A (en) 2012-02-16 2015-03-23 ニューヨーク・ユニバーシティ Control of hypoxia-inducible gene expression by oligooxopiperazine non-peptidic helix mimics
US8993614B2 (en) 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
US9321749B1 (en) 2012-07-25 2016-04-26 Globavir Biosciences, Inc. Heterocyclic compounds and uses thereof
WO2014063155A1 (en) 2012-10-21 2014-04-24 University Of Rochester Thy1 (cd90) as a novel therapy to control adipose tissue accumulation
JP6735561B2 (en) 2012-12-03 2020-08-05 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． O-glycosylated carboxy-terminal portion (CTP) peptide-based insulin and insulin analogs
CN103897041A (en) * 2012-12-24 2014-07-02 杨子剑 Novel compound containing vancomycin structure and preparation method and use thereof
JP6832158B2 (en) 2013-03-14 2021-02-24 アイカーン スクール オブ メディシン アット マウント サイナイ Therapeutic acidic ceramidase composition and how to make and use it
WO2018035281A1 (en) 2016-08-17 2018-02-22 North Carolina State University Northern-southern route to synthesis of bacteriochlorins
WO2018102252A1 (en) 2016-11-30 2018-06-07 North Carolina State University Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
WO2018136779A2 (en) 2017-01-19 2018-07-26 The University Of Chicago OXALOBACTER FORMIGENES(Of)-DERIVED FACTORS FOR THE TREATMENT OF TREATMENT/PREVENTION OF EXCESS OXALATE LEVELS
US10174302B1 (en) 2017-06-21 2019-01-08 Xl-Protein Gmbh Modified L-asparaginase
WO2020152532A1 (en) 2019-01-23 2020-07-30 Enzyvant Therapeutics Gmbh Method of ameliorating a pro-inflammatory immunophenotype in farber disease subjects by repeated administration of a recombinant human acid ceramidase
WO2024026042A1 (en) 2022-07-28 2024-02-01 Atossa Therapeutics, Inc. Heparin compositions for treatment of lung damage and methods of use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3256153A (en) * 1963-02-08 1966-06-14 Smith Kline French Lab Method of stabilizing wax-fat coating materials and product thereof
US4003792A (en) * 1967-07-01 1977-01-18 Miles Laboratories, Inc. Conjugates of acid polysaccharides and complex organic substances
US4044196A (en) * 1972-03-30 1977-08-23 Bayer Aktiengesellschaft Crosslinked copolymers of α,β-olefinically unsaturated dicarboxylic anhydrides
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
FR2408387A2 (en) * 1975-06-30 1979-06-08 Oreal COMPOSITIONS BASED ON AQUEOUS DISPERSIONS OF LIPID SPHERULES
JPS53116315A (en) * 1977-03-17 1978-10-11 Ueno Seiyaku Oyo Kenkyujo Kk Powder or granular containing improved sorbinic acid
US4698264A (en) * 1982-08-02 1987-10-06 Durkee Industrial Foods, Corp. Particulate composition and process for making same
US4585754A (en) * 1984-01-09 1986-04-29 Valcor Scientific, Ltd. Stabilization of proteins and peptides by chemical binding with chondroitin
US4684524A (en) * 1984-03-19 1987-08-04 Alza Corporation Rate controlled dispenser for administering beneficial agent
US4717566A (en) * 1984-03-19 1988-01-05 Alza Corporation Dosage system and method of using same
US4849405A (en) * 1984-05-09 1989-07-18 Synthetic Blood Corporation Oral insulin and a method of making the same
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4622392A (en) * 1984-06-21 1986-11-11 Health Research Inc. (Roswell Park Division) Thiophospholipid conjugates of antitumor agents
US4629621A (en) * 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US4797288A (en) * 1984-10-05 1989-01-10 Warner-Lambert Company Novel drug delivery system
SE457326B (en) * 1986-02-14 1988-12-19 Lejus Medical Ab PROCEDURES FOR PREPARING A QUICK SUBSTANTIAL CANDLES CONTAINING BLA MICROCRISTALLIN CELLULOSA
US5093198A (en) * 1987-06-19 1992-03-03 Temple University Adjuvant-enhanced sustained release composition and method for making
DE3721721C1 (en) * 1987-07-01 1988-06-09 Hoechst Ag Process for coating granules
JPH01308231A (en) * 1988-06-03 1989-12-12 Takeda Chem Ind Ltd Stabilized pharmaceutical composition and production thereof
US5055300A (en) * 1988-06-17 1991-10-08 Basic Bio Systems, Inc. Time release protein
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0452179B1 (en) * 1990-03-28 1996-06-12 Nippon Oil And Fats Company, Limited Polymer-combined drug for gastric treatment and a method for producing the drug
CH683149A5 (en) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Process for the preparation of microspheres of a biodegradable polymeric material.
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5889153A (en) * 1994-05-20 1999-03-30 Hisamitsu Pharmaceutical Co., Inc. Protein or polypeptide, method for producing the same and intermediate compound therefor
WO1997021452A2 (en) * 1995-12-14 1997-06-19 Advanced Magnetics, Inc. Macromolecular prodrugs of nucleotide analogs

Also Published As

Publication number Publication date
CN1192690A (en) 1998-09-09
EP0841936A4 (en) 2001-09-26
IL123106A0 (en) 1998-09-24
AU698944B2 (en) 1998-11-12
JPH11511131A (en) 1999-09-28
US5681811A (en) 1997-10-28
MX9800883A (en) 1998-09-30
AU6640996A (en) 1997-02-26
CA2227891C (en) 2009-04-14
CN1182870C (en) 2005-01-05
WO1997004796A1 (en) 1997-02-13
EP0841936A1 (en) 1998-05-20

Similar Documents

Publication Publication Date Title
CA2227891A1 (en) Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations
CA2162366A1 (en) Conjugation-stabilized polypeptide compositions
EP2626368A3 (en) Insulin-oligomer conjugates, formulations and uses thereof
CA2323048A1 (en) Poly(ethylene glycol) derivatives with proximal reactive groups
WO2001093914A3 (en) Multivalent platform molecules comprising high molecular weight polyethylene oxide
WO2003068144A3 (en) Cytotoxic agents
EP2260858A3 (en) Monomethylvaline compounds capable of conjugation to ligands
IL150153A (en) G-csf conjugates, compositions and uses thereof
IL206445A0 (en) Peptide conjugate of exendin-4(1-39)variant in combination with an antidiabetic agent for use in the treatment of type 2 diabetes mellitus
AU2003221291A1 (en) Hydrophilic polymer derivate with y type branch and preparation method of it medical composite comprising above compound
WO2006091894A4 (en) New polymeric materials and methods
IL142282A0 (en) Compositions containing polymer conjugates of interferon-beta-1a
CA2304976A1 (en) Delivery of poly(ethylene glycol)-conjugated molecules from degradable hydrogels
WO2000041538A3 (en) Dermal compositions
WO2004084950A3 (en) Cell targeting methods and compositions
AU2874099A (en) Low molecular weight compounds administered together with anti-cancer agents to treat cancer and pharmaceutical compositions thereof
JP2002532407A5 (en)
CA2251008A1 (en) Macromolecular complexes for drug delivery
KR890701736A (en) Complex of Peroxide Molecular Displacement Coenzyme
UA100967C2 (en) Normal;heading 1;heading 2;heading 3;POLYMER CONJUGATES OF NEUBLASTIN AND METHODS OF USING SAME
WO2003037272A3 (en) Thymosin alpha 1 peptide/polymer conjugates
JP2003504312A5 (en)
EP1351709B8 (en) Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates
CA2119675A1 (en) Antitumor mitoxantrone polymeric compositions
Choi et al. PEGylation of G-CSF using cleavable oligo-lactic acid linkage

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20160729